Integra LifeSciences (NASDAQ:IART) Reaches New 1-Year Low at $31.53

Integra LifeSciences Holdings Co. (NASDAQ:IART)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $31.53 and last traded at $31.57, with a volume of 232579 shares changing hands. The stock had previously closed at $31.94.

Analysts Set New Price Targets

Several equities analysts have commented on the company. JMP Securities cut their price target on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Truist Financial dropped their target price on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Finally, Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Price Performance

The stock has a market capitalization of $2.49 billion, a P/E ratio of 38.48, a price-to-earnings-growth ratio of 0.96 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The stock has a 50-day simple moving average of $37.32 and a 200 day simple moving average of $39.19.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. During the same quarter in the previous year, the business posted $0.94 earnings per share. The firm’s quarterly revenue was down .3% on a year-over-year basis. On average, equities analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Diversified Trust Co boosted its position in shares of Integra LifeSciences by 37.3% in the 1st quarter. Diversified Trust Co now owns 22,846 shares of the life sciences company’s stock worth $810,000 after purchasing an additional 6,208 shares during the last quarter. Cardinal Capital Management raised its position in Integra LifeSciences by 40.6% during the first quarter. Cardinal Capital Management now owns 31,069 shares of the life sciences company’s stock valued at $1,101,000 after purchasing an additional 8,968 shares in the last quarter. Northwest Investment Counselors LLC acquired a new position in Integra LifeSciences during the first quarter valued at approximately $143,000. Alaska Permanent Fund Corp acquired a new position in shares of Integra LifeSciences during the first quarter worth $457,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Integra LifeSciences by 6.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 33,307 shares of the life sciences company’s stock worth $1,451,000 after buying an additional 1,929 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.